Literature DB >> 7524606

Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.

A Gerl1, C Clemm, N Schmeller, H Dienemann, M Weiss, M Kriegmair, U Löhrs, W Wilmanns.   

Abstract

Thirty-eight patients with advanced non-seminomatous germ cell tumours (NSGCTs) underwent multiple surgical interventions (two in 33 patients, three in four patients, four in one patient) after cisplatin-based chemotherapy. All patients had normal serum tumour markers but persistent radiographic masses. The larger mass was routinely resected first. Fifteen patients (39%) had dissimilar histological findings at sequential surgical procedures, 12 of whom demonstrated less favourable pathological features during the first operation and three at the second. Patients who underwent both retroperitoneal lymph node dissection (RPLND) and lung resection showed less favourable histological features in the retroperitoneum in nine cases and in the lung in three cases. Eight of 16 patients (50%) without mature teratoma in their primary tumours showed complete necrosis/fibrosis at all surgical interventions, whereas all patients whose primary tumour was classified as malignant teratoma intermediate demonstrated mature teratoma at least at one anatomical site. As histology of post-chemotherapy residual masses cannot be extrapolated from one anatomical site to another, patients usually are properly managed by excision of all residual masses. In particular, in patients with necrosis/fibrosis at lung resection omission of RPLND is not advised.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524606      PMCID: PMC2033563          DOI: 10.1038/bjc.1994.429

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit.

Authors:  W F Hendry; R P A'Hern; J W Hetherington; M J Peckham; D P Dearnaley; A Horwich
Journal:  Br J Urol       Date:  1993-02

2.  Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.

Authors:  D P Dearnaley; A Horwich; R A'Hern; J Nicholls; G Jay; W F Hendry; M J Peckham
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis.

Authors:  R P Kulkarni; K W Reynolds; E S Newlands; P M Dawson; A R Makey; N A Theodorou; J Bradley; R H Begent; G J Rustin; K D Bagshawe
Journal:  Br J Surg       Date:  1991-02       Impact factor: 6.939

4.  Significance of salvage lymphadenectomy in the therapeutical concept of advanced nonseminomatous germ cell tumors.

Authors:  G Staehler; M Wiesel; C Clemm; J M Gokel; M Marchner
Journal:  Urol Int       Date:  1989       Impact factor: 2.089

5.  Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.

Authors:  A Gerl; C Clemm; R Lamerz; K Mann; W Wilmanns
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses?

Authors:  H L Qvist; S D Fosså; S Ous; J Høie; A E Stenwig; K E Giercksky
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

7.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.

Authors:  G M Mead; S P Stenning; M C Parkinson; A Horwich; S D Fossa; P M Wilkinson; S B Kaye; E S Newlands; P A Cook
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

8.  Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)

Authors:  R L Jansen; R Sylvester; D T Sleyfer; W W ten Bokkel Huinink; S B Kaye; W G Jones; J Keizer; A T van Oosterom; S Meyer; C P Vendrik
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

Authors:  S D Fosså; H Qvist; A E Stenwig; H H Lien; S Ous; K E Giercksky
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  The extent of surgery after chemotherapy for advanced germ cell tumors.

Authors:  F S Freiha; L D Shortliffe; R V Rouse; J B Mark; J F Hannigan; D Aston; J T Spaulding; R D Williams; F M Torti
Journal:  J Urol       Date:  1984-11       Impact factor: 7.450

View more
  5 in total

1.  Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors.

Authors:  Jörg Thomas Hartmann; Oliver Rick; Karin Oechsle; Markus Kuczyk; Thomas Gauler; Patrick Schöffski; Jan Schleicher; Frank Mayer; Reinhard Teichmann; Lothar Kanz; Carsten Bokemeyer
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

Review 2.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 3.  Management of post-chemotherapy extra-retroperitoneal residual masses.

Authors:  Brett S Carver; Joel Sheinfeld
Journal:  World J Urol       Date:  2009-04-17       Impact factor: 4.226

4.  [Regression of germ cell tumors after chemotherapy].

Authors:  V Loy; U Klenk; J Linke
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

5.  Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.

Authors:  A Gerl; C Clemm; N Schmeller; R Hartenstein; R Lamerz; W Wilmanns
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.